Company news
Traws Pharma, Inc. news in 2026
Traws Pharma, Inc.'s news releases, calls and decks from 2026, newest first.
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
August 14, 2026
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
June 21, 2026
Traws Pharma Provides Regulatory Update on Influenza Program
June 12, 2026
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
May 26, 2026
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
May 15, 2026
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
May 8, 2026
Traws Pharma Announces Up to $60 Million Private Placement Financing
April 14, 2026
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
February 19, 2026
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
January 26, 2026
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
January 13, 2026